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Abstract
Background. Activated infiltrating T cells play a crucial
role in nephritic inflammation via the direct interaction
with proximal tubular epithelial cells (TEC). Under
inflammatory conditions, major histocompatibility
complex class I and II molecules are upregulated on
the surface of renal TEC, enabling them to function as
‘non-professional’ antigen-presenting cells (APC) to
activate T cells, and, in turn to be targeted by cytotoxic
T lymphocytes (CTL) to cause tissue damage. It is
known that co-stimulatory (e.g. B7/CD28) and
co-inhibitory (e.g. PD-L1/PD-1) signals regulate and
determine the magnitude of T cell responses. In this
study, we examined the expression of co-stimulatory
molecule PD-L1 by renal TEC and the functional role
of renal PD-L1/PD-1 pathway in regulating CD8þ T
cell responses induced by antigen-presenting renal
TEC.
Methods. Renal TEC were treated with type I and
type II interferons (IFN-a, IFN-b or IFN-g). PD-L1
expression was then determined with flow cytometry
and RT-PCR. To investigate the functional
role of renal epithelial PD-L1 on CD8þ CTL
responses, H-2Kb-restricted, OVA257–264 peptide-
specific CD8þ T cells isolated from OT-1T cell
receptor transgenic mice were co-incubated with
IFN-stimulated, OVA257–264 peptide-pulsed congeneic
TEC. The activation of OT-1 CD8þ CTL was
estimated either by IFN-g production in the super-
natants of co-cultures or by CTL activity.
Results. TECs do not constitutively express PD-L1 on
their surface. However, a strong and dose-dependent
upregulation of PD-L1 was observed on TEC after
stimulation with IFN-b or IFN-g, but not with IFN-a.
OVA257–264 peptide pulsed-TEC were able to activate
OT-1 CD8þ T cells, indicated by the high amount of
IFN-g production and cytolysis of TEC. Blockade of
epithelial PD-L1 with specific mAb significantly
increased OT-1 CD8þ T cell activity, indicating that
the PD-L1 pathway has a negative effect on CD8þ T
cell responses. Moreover, IFN- b- or IFN-g-stimulated
TEC with high surface PD-L1 expression were more
resistant to the cytolysis by OT-1 CTL.
Conclusion. Together our data reveal that the renal
PD-L1/PD-1 pathway has a negative effect on CD8þ
CTL activation. PD-L1 might, therefore, act as a
protective molecule on TEC, downregulating the
cytotoxic renal parenchymal immune response.
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Introduction
The proximal renal tubular epithelium is an important
target in tubulointerstitial immune-mediated kidney
diseases [1]. Activated infiltrating T cells play a crucial
role in nephritic inflammation via the direct interaction
with renal proximal tubular epithelial cells (TEC).
Thus, infiltrating CD4þ and CD8þ T cells surrounding
the tubular epithelium are found in abundance in most
tubulointerstitial disease processes, including tubuloin-
terstitial nephritis and renal allograft rejection [2,3].
The ability of renal TEC to promote T cell activation is
attributable to their expression of major histocompat-
ibility complex (MHC) class I and class II molecules
and co-stimulatory molecules. Renal TECs act as
non-professional antigen-presenting cells (APC) to
trigger specific T cell responses, and can in turn be
targeted by antigen-specific cytotoxic T cells (CTL)
during immune-mediated kidney diseases. Although it
is well known that CD8þ T cells are the predominant
effector cells in tubulointerstitial renal injury and
allogeneic kidney transplantation, the regulatory
mechanisms of CD8þ T cell responses to TEC
have not been fully elucidated yet [4–8]. In particular,
studies examining the role played by B7-related
Correspondence and offprint requests to: Dr Y. Waeckerle-Men,
Institute of Physiology, University of Zurich-Irchel,
Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
Email: ying.waeckerle-men@access.unizh.ch
Nephrol Dial Transplant (2007) 22: 1527–1536
doi:10.1093/ndt/gfl818
Advance Access publication 5 March 2007
 The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
co-stimulatory molecules on CD8þ T cell responses to
TEC are lacking.
Co-stimulatory pathways effectively regulate T cell
activation and tolerance [9,10]. The classical
co-stimulatory molecules expressed on professional
APC include B7.1, B7.2 and CD40. Interactions of
B7/CD28 and CD40/CD40L provide positive
signals to upregulate T cell responses, whereas the
B7/CTLA-4 pathway leads to suppression of T cell
responses. Recently, several novel co-stimulatory
and co-inhibitory molecules have been discovered.
A negative T cell regulatory pathway which could
potentially be important for immune-mediated tubu-
lointerstitial injury is represented by the interaction
between programmed death-1 (PD-1) expressed on
activated T cells, and its two ligands PD-L1 and PD-L2
which are expressed on APC [9–11]. Recently, we and
others have described that PD-L1 is strongly upregu-
lated by TEC in rejected kidney transplants as well as
in inflamed kidneys [2,3,12], suggesting that it may
play an important regulatory role in immune-mediated
renal injury.
We and others have previously shown that IFN-g
treatment rapidly and strongly upregulated PD-L1 but
not PD-L2 on cultured murine TEC, and that blockade
with mAbs of PD-L1 on TEC significantly increased
antigen-specific CD4þ T cell responses [2]. Thus far the
functional role of the renal epithelial PD-L1/PD-1
pathway in CD8þ CTL responses has not been
investigated. In this study we first examined in detail
the differential effect of type I and type II interferons
(IFNs) on PD-L1 and MHC class I expression in
renal TEC, then examined the functional role of the
PD-L1/PD-1 pathway on the antigen-specific activa-
tion of CD8þ T cells by TEC, and the cytolytic effect to
TEC by activated CD8þ CTL.
Materials and methods
General reagents
Cell culture reagents were obtained from Invitrogen
(Gaithersburg, MD) and Sigma (St. Louis, MO). Recombi-
nant mouse IFN-a, IFN-b and IFN-g were purchased from
R&D Systems (Oxford, UK). Anti-mouse PD-L1, PD-1 and
MHC class I monoclonal antibodies (mAbs) were purchased
from eBioscience (San Diego, CA). Biotin-conjugated anti-
mouse H-2Kk was obtained from BD Biosciences (San Jose,
CA). Chicken ovalbumin peptide 257-264 (OVA257–264,
amino acid sequence SIINFEKL) was purchased from
Proimmune (London, UK). A control H-2Kb restricted
b-galactosidase peptide 497–504 (b-Gal497–504, amino acid
sequence ICPMYARV) was a kind gift from Prof. Groettrup
of Constance University, Germany. Anti-mouse CD8a (Ly-2)
MACS microbeads were obtained from Miltenyi Biotec
(Bergisch Gladbach, Germany).
Animals, cell lines and renal proximal TEC cultures
T cell receptor (TCR) transgenic OT-1 mice [13] were
obtained from Jackson Laboratories (Bar Harbor, ME).
C57BL/6 (B6) and C3H/HeN (C3H) mice were purchased
from Harlan (Horst, Netherlands). All animals were used at
8–16 weeks of age. The study protocol was approved by the
regulatory commission for animal studies of the Canton
Zurich, Switzerland. Primary cultures of murine renal
proximal TEC were prepared as described previously [14].
Primary renal TEC and SV40-transformed murine renal
proximal TEC line C1.1 were cultured on collagen-coated cell
culture plates in modified K1 medium as previously
described [14]. A murine macrophage cell line RAW 264.7
and EL-4 cells were grown in complete Dulbecco’s modified
Eagle’s medium (DMEM) with Glutamax, supplemented
with 1000U/ml penicillin, 100mg/ml streptomycin and
10% FBS. All cells were maintained at 378C with 5% CO2.
RNA extraction and RT-PCR analysis
Total RNA from cell cultures was extracted using the
RNeasy mini kit (Qiagen, Valencia, CA). All samples
were quantified by the measurement of the optical density
at 260 nm, and equal amounts were amplified by reverse
transcription-polymerase chain reaction (RT-PCR) (Qiagen
OneStep PCR kit, Qiagen). Primer sequences of PD-L1
were determined as previously described [2]. To ensure
even amounts of template, the rat housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
co-amplified as described previously [15]. Reaction mixtures
were separated on 1.5% agarose gels containing ethidium
bromide, and bands were detected under UV light
and analysed with the Bio-Image System ChemidocTM
XRS (Bio-Rad, Hercules, CA).
Flow cytometric analysis
RAW264.7, the renal TEC line C1.1 and primary cultures of
renal TEC were stimulated with IFN-a, IFN-b or IFN-g
for 48 h. Cells were harvested by light trypsinization, washed
twice with Hanks’ Balanced Salt Solution (HBSS, Invitrogen)
and suspended in PBS containing 2% FBS and 0.1% sodium
azide. Before staining with the primary antibody, macro-
phages were pre-incubated with anti-mouse CD16/CD32 Ab
for 15min to block FcR binding. After incubating with
primary mAbs for 45min on ice, cells were washed twice and
incubated with the appropriate FITC-conjugated secondary
Ab for 30min. Cells were then washed and analysed using an
FACScan flow cytometer and the Cell QuestTM software
(Becton Dickinson).
Isolation of CD8þ T cells from OT-1 mice
Spleen and lymph nodes (LN) were harvested from 8–16-
week-old naı¨ve OT-1 mice. CD8þ cells were isolated using
anti-mouse CD8a (Ly-2) MACS microbeads according to the
manufacturer’s protocol. The freshly isolated OT-1 CD8þ T
cells were either used immediately for antigen presentation
assays, or were activated in vitro. To activate OT-1 CTL,
OT-1 CD8þ T cells were stimulated with B6 splenocytes
pulsed with 0.1mg/ml of OVA257–264 peptide and were
incubated in DMEM medium supplemented with 5 mM
2-mercaptomethanol, 1% HEPES, 1000U/ml penicillin,
100mg/ml streptomycin and 10% FBS at a T cell to APC
ratio of 1:5. After 6 days of stimulation, activated OT-1 CTL
were used for CTL assays.
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Antigen presentation of renal B6 TEC to
resting OT-1 CD8þ T cells
To study the antigen presentation of the H-2Kb-restricted
peptide OVA257–264 by congeneic primary TEC to OT-1
CD8þ T cells, B6 primary TEC were pre-treated with IFNs
for 48 h. Cells were washed to remove excess cytokines and
were harvested by light trypsinization. The cells were then
pulsed with 0.1mg/ml of OVA257–264 peptide or the control
H-2Kb-restricted b-Gal497–504 peptide for 1 h at 378C. After
washing, TEC were counted and seeded in 96-well U-bottom
cell culture plates (Costar) in DMEM medium supplemented
with 5% FBS, 1000U/ml of penicillin and 100mg/ml of
streptomycin. The resting OT-1 CD8þ T cells were added to
TEC cultures and were co-incubated at 378C. Anti-mouse
PD-L1 mAb (10 mg/ml) were added to TEC 1h prior to the
addition of OT-1 CD8þ T cells as indicated. After 24 h,
supernatants from co-cultures were collected and analysed
for IFN-g content using a mouse IFN-g-specific ELISA kit
(OptEIATM mouse IFN-g kit, BD Pharmingen). In control
experiments, OVA257–264 or b-Gal497–504 peptide-pulsed EL-4
cells were used.
IFN-g enzyme-linked immunosorbent spot (ELISPOT)
assays (Diaclone, Besanc¸on, France) were also used to
determine the IFN-g production induced by resting OT-1
CD8þ T cells after activation by OVA257–264-presenting
congeneic TEC. Briefly, untreated B6 TEC or EL-4 cells were
pulsed with 0.1 mg/ml of OVA257–264 or b-Gal497–504 peptide
for 1 h at 378C. The cells were then washed and seeded into
the ELISPOT plate. Resting OT-1 CD8þ T cells were added
to the TEC cultures and were co-incubated for 18 h at 378C.
ELISPOT plates were developed according to the manufac-
turer’s protocol.
Cytotoxicity by activated OT-1 CD8þ CTL to B6 TEC
To measure antigen-specific cytolysis of renal TEC
by CTL, activated OT-1 CD8þ CTL were added to
IFN-pre-treated, OVA257–264 peptide-loaded B6 TEC
in 96-U bottom cell culture plates at various effector/target
(E/T) ratios, in the presence or absence of anti-mouse
PD-L1 mAb (10 mg/ml). After 4 h of incubation, 50 ml of
supernatants were collected from each well for measuring
the amount of lactate dehydrogenase (LDH) released upon
cell lysis by using the CytoTox 96 non-radioactive
cytotoxicity assay kit (Promega) according to the
manufacturer’s protocol. The percentage of target lysis was
calculated as follows:
% lysis ¼100 ðexperimental LDH release spontaneous
LDH release of targets spontaneous LDH
release from T cellsÞ=ðmaximum LDH release
 spontaneous LDH release of targetsÞ:
Statistics
Results from IFN-g ELISA, ELISPOT or CTL assays are
expressed as means SD of triplicate or quadruplicate
determinations from the representative experiments that
gave rise to similar results. Statistical analysis was performed
using unpaired Student’s t-test. Significance was accepted at
P 0.05.
Results
Stimulation of renal proximal TEC with IFN- and
IFN- upregulated PD-L1
Murine macrophage RAW246.7 cells and murine
primary proximal TEC cultures prepared from
C57BL/6J (B6 TEC) mice were stimulated with
200U/ml of IFN-b or 100U/ml of IFN-g for 1–4 h
for determining changes in mRNA expression of
PD-L1. As shown in Figure 1, PD-L1 mRNA
was constitutively detected in macrophages and renal
TEC. A strong increase of steady-state PD-L1 mRNA
levels was observed in macrophages after 1 and 4 h of
stimulation with either IFN-b or IFN-g (Figure 1A),
in renal B6 TEC after 1 and 4 h of stimulation with
IFN-b, and slightly delayed after 4 h with IFN-g
(Figure 1B). Stimulation of TEC with IFN-a even
at a higher concentration (up to 1000U/ml) did
not increase PD-L1 mRNA expression in TEC (data
not shown).
The surface expression of PD-L1 and MHC class I
on TEC was examined after stimulation with IFN-b or
IFN-g for 48 h. Expression of PD-L1 on untreated
C1.1 or primary C3H renal TEC cultures (the original
of C1.1 cells) was negligible, contrasting with RAW
264.7 macrophages which constitutively express sur-
face PD-L1 (Figure 2A). Stimulation with IFN-b or
IFN-g strongly upregulated PD-L1 (Figure 2A) and
MHC class I molecules (Figure 2B) on all cells tested.
The upregulation of both PD-L1 and MHC class I
molecules on IFN-b or IFN-g-stimulated renal TEC
was dose-dependent (our previous results [2] and
Figure 3). Although stimulation of TEC with IFN-a
did not increase PD-L1 surface expression even when a
high dose (1000U/ml) was used, a dose-dependent,
strong increase of MHC class I expression was
observed (Figure 3B), suggesting that IFN-a
and IFN-b use different pathways to activate
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Fig. 1. RT-PCR analysis of PD-L1 mRNA expression in renal TEC
treated with IFNs. Murine macrophage RAW264.7 cells (positive
control cell line) (A) and primary renal TEC cultures generated
from B6 mice (B) were treated with IFN-b (200U/ml) or IFN-g
(100U/ml) for 1 or 4 h. Results are representative of two independent
experiments which gave similar results.
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antigen-presenting cells. Similar results were also
obtained by IFN-stimulation of primary TEC that
were generated from different mouse strains, including
C57BL/6, C3H, BALB/c and AKR/J (data not
shown), indicating that this phenomenon is not limited
to a specific cell line or mouse strain.
Activation of resting OT-1 CD8þ T cells by TEC
We used CD8þ T cells isolated from OT-1 TCR
transgenic mice to examine the ability of renal TEC to
present MHC class I-restricted antigenic peptide. OT-1
mice contain transgenic TCR genes in CD8þ T cells,
which are designed to recognize the chicken ovalbumin
protein residues 257–264 in the context of H-2Kb
(OVA257–264) [13]. FACS analysis showed that resting
OT-1 CD8þ T cells express PD-L1 but not PD-1,
whereas both molecules were strongly upregulated on
in vitro-activated OT-1 CTL (Figure 4).
Antigen titration experiments were then performed
to examine the capacity of presenting OVA257–264
peptide to the resting OT-1 CD8þ T cells by renal B6
TEC. Similar amounts of IFN-g were detected from
supernatants of OT-1 CD8þ T cell cultures sensitized
either by OVA257–264 pulsed congeneic TEC (from
C57BL/6 mice) or by EL-4 cells (Figure 5A). These
results were further confirmed by IFN-g ELISPOT
assays. As shown in Figure 5B and C, resting OT-1
CD8þ T cells activated by either OVA peptide-
presenting B6 TEC or EL-4 cells gave rise to a
comparable level of IFN-g production when captured
and visualized by IFN-g ELISPOTs. These results
demonstrate that renal TEC have a strong capacity of
presenting MHC class I-restricted antigenic peptides to
activate antigen-specific CD8þ T cells in vitro.
PD-L1 on renal TEC inhibited antigen presentation
to OT-1 CD8þ T cells
We studied next whether PD-L1 was able to regulate
CD8þ T cell responses. For this purpose, TEC were
first stimulated with IFN-b or IFN-g for 48 h to
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Fig. 2. PD-L1 and MHC class I expression on renal TEC stimulated with IFN-b (200U/ml) or IFN-g (100U/ml) for 48 h. Murine
macrophage line RAW264.7, renal TEC line C1.1 and primary TEC cultures generated from C3H mice (18 TEC) were stained with anti-
mouse PD-L1 (A) or MHC class I (B) mAbs for flow cytometric analysis. Results are representative of four independent experiments.
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upregulate PD-L1. Cells were then collected, washed
and loaded with OVA257–264 peptide. Anti-PD-L1 mAb
was added to block PD-L1 on TEC before activating
the resting OT-1 CD8þ T cells. Blockade of PD-L1
significantly increased OT-1 CD8þ T cell activation, as
revealed by higher amounts of IFN-g, compared to
those with TEC without PD-L1 blockade (Figure 6).
The reaction was antigen-specific and MHC class
I-restricted, since irrelevant b-Gal497–504 peptide-pulsed
TEC failed to induce OT-1T cell activation and C1.1
cells (H-2Kk) pulsed with OVA257–264 peptide did not
induce IFN-g production by OT-1T cells (data not
shown). These results indicated that PD-L1-expressing
renal epithelial cells modulated the antigen-specific
CD8þ T cell activation.
PD-L1 partially protected TEC from cytolysis
by OT-1 CTL
We then examined whether OVA-presenting TEC
would be the direct targets of OT-1 CD8þ CTL, and
whether epithelial PD-L1 plays a functional role on
CTL responses. For this purpose, OVA257–264 peptide-
pulsed B6 renal TEC, pretreated with IFN-a, IFN-b
and IFN-g or untreated, were used as target cells to
study the cytotoxicity of OT-1 CD8þ T cells. Resting
OT-1 CD8þ T cells isolated from naı¨ve OT-1
mice failed to kill OVA257–264 peptide-presenting
target cells, including renal B6 TEC or EL-4 cells
(data not shown). In contrast, in vitro-stimulated/
activated OT-1 CD8þ T cells demonstrated a strong
cytotoxicity when OVA257–264 peptide-presenting B6
TEC or EL-4 cells were used as targets (Figure 7A).
Only basal cytolysis of target cells was observed when
TEC and EL-4 cells were pulsed with the irrelevant
H-2Kb peptide b-Gal497–504 (Figure 7A). Importantly,
when IFN-b and IFN-g-stimulated TEC were used as
targets in the same CTL assay, significantly lower
cytolysis was observed compared with untreated TEC.
The lysis of TEC treated with IFN-a did not show
significant difference when compared with untreated
TEC (Figure 7A). Considering that IFN-b or IFN-g
treatment upregulated high-surface PD-L1 molecule
expression, this may be indirect evidence that the
surface PD-L1 protects TEC from the cytolysis by
CTL. To further clarify this point, anti-PD-L1 anti-
bodies were added to block the surface PD-L1 during
CTL assay. As shown in Figure 7B, the PD-L1 Ab
blockade led to a significant increase of cytolysis of
TEC treated with IFN-b or IFN-g, respectively, while
adding anti-PD-L1 mAb to untreated or IFN-a-treated
TEC did not alter the cytolytic effect of OT-1 CD8þ T
cells. Taken together, these results demonstrate that
PD-L1 expressed on renal TEC plays an inhibitory role
on CTL responses, reducing T cell activation and
protecting TEC from the killing by CD8þ CTL.
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Fig. 3. PD-L1 and MHC class I expression on renal TEC stimulated
with type I IFNs. C1.1 cells were stimulated with the indicated
concentrations of IFN-a or IFN-b for 48 h, and were stained with
anti-mouse PD-L1 (A) or MHC class I (B) mAbs for flow cytometric
analysis. Results are representative of two independent experiments.
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Fig. 4. Flow cytometric analysis of PD-1 and PD-L1 expression on
OT-1 CD8þ T cells. Resting or OVA257–264 peptide-stimulated OT-1
CD8þ T cells were stained with anti-mouse PD-1 or PD-L1 mAbs for
flow cytometric analysis. Results are representative of two indepen-
dent experiments.
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Discussion
In this study we demonstrate that the expression of
PD-L1 on TEC is strongly and rapidly upregulated by
IFN-b and IFN-g, but not by IFN-a. Furthermore, we
show that the PD-L1/PD-1 pathway inhibits antigen-
specific CD8þ T cell activation by renal TEC. In
addition, the blockade of PD-L1 on TEC leads to
an enhanced cytolytic activity of CTL in an MHC class
I-restricted manner. PD-L1 on renal TEC, therefore,
provides a negative signal for antigen-specific CD8þ T
cell responses.
CD8þ T cells are major contributors in cell-mediated
immune responses in tubulointerstitial renal diseases
and are responsible for the tubular destruction [4,16].
However, the mechanisms that regulate the intrarenal
CD8þ T cell activity have not been investigated in
detail. Apart from MHC class I complex/TCR inter-
actions that are crucial for initiating T cell activation,
a variety of co-stimulatory and co-inhibitory pathways
are known to influence the cytolytic potential of
CD8þ T cells [9,10,17]. Among those co-stimulatory
pathways, B7/CD28 provides the most prominent
activation signal for CD8þ T cells. However, as B7.1
and B7.2 are hardly expressed by renal TEC, the
relevant co-stimulatory pathways might be different
for TEC-driven CD8þ T cell responses. Similarly, the
co-inhibitory B7/CTLA-4 interaction might also not
operate on TEC for the same lack of expression
of B7 molecules. Considering that only limited
co-stimulatory or co-inhibitory molecules such as
PD-L1, ICOS-L and CD40 are expressed in renal
TEC (our unpublished data), thus PD-L1 may be one
of the major co-inhibitory molecules regulating
renal epithelial CD8þ CTL responses. Our current
findings that the epithelial PD-L1/PD-1 pathway
has an immunological regulatory function on CD8þ
CTL responses are also consistent with other studies,
including cancer immunity, pathogen-induced CD8þ T
cell responses, autoimmune diseases and organ
transplantation [9,10,18].
PD-L1 is aberrantly expressed by various
human carcinomas [18–23]. The expression of
PD-L1 by tumour cells can impair tumour-specific
A
IF
N
-γ
 
pr
od
uc
tio
n 
(pg
/m
l)
OVA257–264 peptide (ng/ml)
0
200
400
600
800
100 10 1 0.1 0.01 0
B6 TEC
EL-4
C
B6
TEC
EL-4
OVA
257–264
β-Gal
497–504
OT-1 T cell
Alone
APC
Alone
OVA257–264 :
β-Gal497–504 :
OT-1 T cells:
APC:
+
−
+
+
−
+
+
+
−
−
+
−
−
−
−
+
Sp
ot
s 
pe
r 5
×
10
4 
O
T-
1 
T 
ce
lls
0
50
100
150
200
250
B6 TEC
EL-4
B
Fig. 5. OVA-presenting renal TEC activate resting OT-1 CD8þ T cells to produce high amounts of IFN-g. (A) Antigen titration assay.
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with resting OT-1 CD8þ T cells (5 104 per well). After 24 h, OT-1 CD8þ T cell activation was determined with IFN-g ELISA. Results
represent the mean amount of IFN-g SD. (B and C) IFN-g ELISPOT assay. Untreated B6 TEC or EL-4 cells (1 104 per well) were pulsed
with 100 ng/ml of OVA257–264 or b-Gal497–504 peptide, then were co-incubated with resting OT-1 CD8
þ T cells (5 104 per well) in pre-coated
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T cell functions, resulting in defective host anti-tumour
immunity. For example, high PD-L1 expression in
human renal cell carcinomas is correlated with tumour
invasiveness and markedly increased the risk of death
from cancer [19]. In an animal study, resistance of PD-
L1-positive tumour cells to the cytolysis by tumour-
specific CTL has been observed, and this could
be abrogated by the treatment with anti-PD-L1 or
anti-PD-1 antibodies [24].
Interesting results have been obtained regarding the
role of PD-L1 in chronic infections. Barber et al. [25]
demonstrated that the in vivo blockade of either PD-L1
or its receptor PD-1 with antibodies enhanced lym-
phocytic choriomeningitis virus (LCMV)-specific
CD8þ T cell responses, and restored the function
of those ‘exhausted’ CD8þ T cells during chronic
LCMV infection. It is tempting to speculate that the
IFN-stimulated expression of PD-L1 on TEC could
protect intratubular viruses such as Epstein–Barr or
the BK polyoma virus, promoting, therefore, their
cytopathic effects [26,27].
PD-L1 is also an important control molecule
in autoimmunity and transplant rejection. Mice that
are deficient in PD-L1 and/or PD-1 have a strong
tendency to develop autoimmune diseases [28,29].
In disease models such as autoimmune diabetes
and experimental autoimmune encephalomyelitis
(EAE), upregulated PD-L1 expression has been
observed [30–33]. Enhanced expression of PD-L1 has
also been reported in allograft transplants of kidney,
heart, skin and islets of pancreas, indicating that
PD-L1 plays a role in the downregulation of the
rejection process [2,34–36]. Finally, PD-L1 is involved
in feto-maternal tolerance mechanisms [37]. Together,
these data suggest that the PD-L1/PD-1 pathway plays
an important role in peripheral and parenchymal
immune tolerance.
During inflammation, the tubulointerstitium and/or
TEC are exposed to many pro-inflammatory cytokines
that are produced by infiltrating immune cells. We
have previously reported that IFN-g treatment led to
the strong increase of PD-L1 expression in TEC [2]. An
additional important finding in this study is that the
type I interferon IFN-b is able to induce strong PD-L1
expression in TEC and that the IFN-b-induced PD-L1
on TEC reduced specific CD8þ CTL responses. IFN-b
is the principal immune modulation agent to treat
patients with multiple sclerosis (MS) [38–40].
Schwarting et al. [41] reported that IFN-b treatment
prolonged survival of MRL-Faslpr mice with experi-
mental systemic lupus erythematosus (SLE) and
reduced kidney pathology. The molecular mechanisms
of IFN-b treatment on autoimmune diseases still
remain unclear, but one hypothesis might be that the
administration of IFN-b is able to induce an upregula-
tion of PD-L1 on peripheral professional APC and on
non-lymphoid tissues, thereby downregulating T cell
proliferation and the infiltration of leukocytes. Indeed,
Schreiner et al. [40] showed that the therapeutic
application of IFN-b leads to a significant increase of
PD-L1 level in MS patients, suggesting that PD-L1
might be responsible, at least in part, for the protective
effect in this therapy. More detailed studies are
required to test this hypothesis
IFN-g is a pivotal pro-inflammatory cytokine in
immune-mediated renal diseases [42]. However, its
immunoregulatory effect in vivo is still unclear so far.
Some studies showed that IFN-g is essential for the
disease development [43,44]; whereas others reported
that endogenous IFN-g plays a protective role in renal
organ-specific autoimmunity [45]. Although IFN-g
treatment showed immunoregulatory effect to down-
regulate specific CTL responses under our in vitro
experimental conditions, its in vivo role of organ-
specific immunomodulation still needs to be
elucidated.
The results obtained from the current study
were based on an in vitro experimental system
that used primary TEC cultures and antigen-specific
CD8þ CTL from OT-1 transgenic mice to study the
co-stimulatory function of epithelial PD-L1.
The in vivo role of intrarenal PD-L1 on modulating
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Fig. 6. Blockade of PD-L1 on renal TEC increased OVA
peptide-specific OT-1 CD8þ T cell activation. IFN-b (A) or
IFN-g (B) stimulated, OVA257–264 or b-Gal497–504 peptide-pulsed
(100 ng/ml) renal B6 TEC (2 104 per well) were co-incubated with
resting OT-1 CD8þ T cells (1 105 per well) in the presence or
absence of the PD-L1 blocking mAbs (final concentration 10 mg/ml)
for 24 h. OT-1 CD8þ T cell activation was determined by IFN-g
production from the collected supernatants with IFN-g ELISA.
Data represent the mean amount of IFN-g SD. One out of the four
independent experiments is shown. *P 0.05; **P 0.001, when
compared with TEC without Ab blockade (Student’s t-test).
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T cell responses requires further verification.
Nevertheless, considering the evidence that the in vivo
PD-L1 expression is markedly enhanced in kidneys
with tubulitis in renal allograft rejection [2] and in
lupus nephritis [46], and our previous findings that the
renal epithelial PD-1/PD-L1 pathway inhibits antigen-
specific CD4þ T helper cell activation in vitro [2], our
data indicated that the renal epithelial PD-L1/PD-1
pathway may inhibit both CD4þ and CD8þ T cell
responses and protect the renal epithelial cells from the
attack of CTL.
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Fig. 7. High PD-L1-expressing TEC were partially protected from cytolysis by activated OT-1 CD8þ CTL. (A) IFN-a, IFN-b or IFN-g
treated or untreated renal B6 TEC or EL-4 cells pulsed with 10 ng/ml of OVA257–264 or b-Gal497–504 peptide were co-incubated
with activated OT-1 CD8þ CTL as an E/T ratio 10:1 (1 105 of CTL to 1 104 of TEC per well) for CTL assay. After 4 h of incubation,
specific cytolysis of targets was measured with the CytoTox 96 non-radioactive cytotoxicity assay and calculated as described in
‘Materials and methods’. *P 0.05; **P 0.001, when compared with untreated TEC (Student’s t-test). (B) CTL assay was performed
by using IFN-a, IFN-b or IFN-g pre-treated or untreated, OVA257–264 peptide-pulsed B6 TEC as targets as described in (A), in the presence
or absence of anti-mouse PD-L1 mAb (10 mg/ml). TEC pulsed with b-Gal497–504 peptide was used as control. Data represent the mean %
lysis SD. One out of three independent experiments is shown. *P 0.05; **P 0.001, when compared with TEC without Ab blockade
(Student’s t-test).
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